The Importance of Early Intervention in CHF – Signs and sYmptom Relief

Francis GS. Neurohumoral mechanisms involved in congestive heart failure. Am J Cardiol 1985; 55:15A–21A.

Schunkert H , Sadoshima J , Cornelius T. Angiotensin II-induced growth responses in isolated adult rat hearts. Evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 1995; 76: 489–97.

Jacobi J , Schlaich MP , Delles C , Schobel HP , Schmieder RE. Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. Am J Hypertens 1999; 12(4 Part 1): 418–22.

Pratt RE. Angiotensin II and the control of cardiovascular structure. J Am Soc Nephrol 1999; 10 Suppl 11:S120–8.

Schunkert H , Dzau VJ , Tang SS , Hirsch AT , Apstein CS , Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 1990; 86: 1913–20.

Koilpillai C , Quinones MA , Greenberg B. Relation of ventricular size and function to heart failure status and ventricular dysrhythmia in patients with severe left ventricular dysfunction. Am J Cardiol 1996; 77: 606–11.

The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302.

Pouleur H , Konstam MA , Benedict CR. Progression of left ventricular dysfunction during enalapril therapy: relation ship with neurohormonal reactivation. Circulation 1993; 88 Suppl I:I-293A.

Aldigier JC , Huang H , Dalmay F. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 1993; 21: 289–95.

Holmer SR , Hense HW , Danser AH , Mayer B , Riegger GA , Schunkert H. Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. Heart 1998; 80: 45–8.

Schunkert H. , Ingelfinger JR , Hirsch AT. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res 1993; 72: 312–8.

Jorde UP , Ennezat PV , Lisker J. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000; 101: 844–6.

Cohn JN. Preventing congestive heart failure. Am Fam Physician 1998; 57: 1901–4.

Brater DC. Diuretic therapy. N Engl J Med 1998; 339: 387–95.

Cody RJ , Kubo SH , Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med 1994; 154: 1905–14.

Knowlton KU , Michel MC , Itani M. The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem 1993; 268: 15374–80.

Simons M , Downing SE. Coronary vasoconstriction and catecholamine cardiomyopathy. Am Heart J 1985; 109: 297–304.

Billman GE , Castillo LC , Hensley J , Hohl CM , Altschuld RA. Beta₂-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta₂-adrenergic stimulation in animals susceptible to sudden death. Circulation 1997; 96: 1914–22.

Kaumann AJ , Sanders L. Both beta 1- and beta 2-adreno-ceptors mediate catecholamine-evoked arrhythmias in isolated human atrium. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 536–40.

Barr CS , Lang CC , Hanson J , Arnott M , Kennedy N , Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76: 1259–65.

Rocha R , Chander PN , Khanna K , Zuckerman A , Stier CT Jr . Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31(1 Part 2):451–8.

Weber KT , Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71: 3A–11A.

Pitt B , Zannad F , Remme WJ , Cody RJ. Spironolactone appears beneficial regardless of ejection fraction: the RALES Trial. Circulation 1999; 100 Suppl 1:I-298.

Akera T , Baskin SI , Tobin T , Brody TM. Ouabain: temporal relationship between the inotropic effect and the in vitro binding to, and dissociation from, (Na⁺ + K⁺)-activated ATPase. Naunyn Schmiedebergs Arch Pharmacol 1973; 277: 151–62.

Thames MD. Acetylstrophanthidin-induced reflex inhibition of canine renal sympathetic nerve activity mediated by cardiac receptors with vagal afferents. Circ Res 1979; 44: 8–15.

Ferguson DW , Berg WJ , Sanders JS , Roach PJ , Kempf JS , Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989; 80: 65–77.

Torretti J , Hendler E , Weinstein E , Longnecker RE , Epstein FH. Functional significance of Na-K-ATPase in the kidney: effects of ouabain inhibition. Am J Physiol 1972; 222: 1398–405.

The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–33.

Packer M , O'Connor CM , Ghali JK. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107–14.

Cohn JN , Ziesche S , Smith R. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96: 856–63.

Levine TB. The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil). Clin Cardiol 1997; 20: 320–6.

Elkayam U. Presentation of the results of the MACH-1 Trial. XXI Congress of the European Society of Cardiology, 25 August, 1998.

Packer M , Cohn JN , Abraham WT. , on behalf of the Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83 (2A):27A–28A.

Cohn JN , Johnson G , Ziesche S. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10.

The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988; 259: 539–44.

Packer M , Kessler PD , Gottlieb SS. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgrad Med J 1986; 62 Suppl 1: 179–82.

Israili ZH , Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234–42.

CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet 1999; 353: 9–13.

The International Steering Committee. Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 1997; 80 (9B):54J–58J.

Colucci WS , Packer M , Bristow MR. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996; 94: 2800–6.

Patterson JH , Adams KF Jr , Applefeld MM , Corder CN , Masse BR. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy 1994; 14: 514–21.

Parker JO. The effects of oral ibopamine in patients with mild heart failure - a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. Int J Cardiol 1993; 40: 221–7.

Francis GS , Benedict C , Johnstone DE. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724–9.

Packer M , Lee WH , Medina N , Yushak M , Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987; 106: 346–54.

Richardson A , Bayliss J , Scriven AJ , Parameshwar J , Poole-Wilson PA , Sutton GC. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet 1987; 2: 709–11.

Sherman LG , Liang CS , Baumgardner S , Charuzi Y , Chardo F , Kim CS. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther 1986; 40: 587–94.

Cody RJ , Franklin KW , Laragh JH. Postural hypotension during tilt with chronic captopril and diuretic therapy of severe congestive heart failure. Am Heart J 1982; 103(4 Part 1): 480–4.

Massie B , Kramer B , Haughtom F. Postural hypotension and tachycardia during hydralazine-isosorbide dinitrate therapy for chronic heart failure. Circulation 1981; 63: 658–64.

Wilson JR , Reichek N , Dunkman WB , Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med 1981; 70: 234–9.

Steiness E , Olesen KH. Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy. Br Heart J 1976; 38: 167–72.

Granger G , Ertl G , Kuch J. , on behalf of the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Investigators. A randomized trial evaluating tolerability of candesartan cilexetil for patients with congestive heart failure and intolerance to angiotensin converting enzyme inhibitors. Eur Heart J 1998; 19 Suppl: 133.

McKelvie RS , Yusuf S , Pericak D. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Pilot Study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056–64.

Riegger GA , Bouzo H , Petr P. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation 1999; 100: 2224–30.

Takeda , 1999. Study of the 3-month haemodynamic effects of 2 mg, 4 mg, and 16 mg candesartan cilexetil (TCV-116) in patients with impaired left ventricular function (heart failure - NYHA class II/III). A double-blind, randomised, placebo-controlled, multi-centre study. (Data on file).

Pitt B , Segal R , Martinez FA. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997; 349: 747–52.

Pitt B , Poole-Wilson PA , Segal R. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.

Cohn JN. Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial. Cardiology 1999; 91 Suppl 1: 19–22.

Swedberg K , Pfeffer M , Granger C. Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. Charm Programme Investigators. J Card Fail 1999; 5: 276–82.